Clinical Trial Update: Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing regorafenib plus sintilimab versus regorafenib alone as second-line therapy for non-resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Regorafenib (regorafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: UNKNOWN